MitoNEET: A New Approach for Designing Diabetes Drugs
The overall structure is described as a beta rich domain with a strand swap from opposite ends of the primary structure that forms a ‘beta cap’ domain. Crystallographic analysis was performed on isolated and truncated mitoNEET protein (AA33-108) to determine the precise structure of the novel fold. The Fe-S clusters are 16A from each other, oriented close to the outer mitochondrial membrane. Pioglitzaone, a member of the thiazolidinedione class of insulin-sensitizing drugs has always been thought to work thru the nuclear receptor PPAR-gamma by effecting lipid metabolism and oxidative capacity. Investigators at UC San Diego have demonstrated that it also binds to the 2FE-2S binding site of mitoNEET.
The overall structure is described as a beta rich domain with a strand swap from opposite ends of the primary structure that forms a ‘beta cap’ domain. Crystallographic analysis was performed on isolated and truncated mitoNEET protein (AA33-108) to determine the precise structure of the novel fold. The Fe-S clusters are 16A from each other, oriented close to the outer mitochondrial membrane. Pioglitzaone, a member of the thiazolidinedione class of insulin-sensitizing drugs has always been thought to work thru the nuclear receptor PPAR-gamma by effecting lipid metabolism and oxidative capacity. Investigators at UC San Diego have demonstrated that it also binds to the 2FE-2S binding site of mitoNEET.
Patent Number: US8350007B2
Application Number: US2010673469A
Inventor: Jennings, Patricia A | Dixon, Jack | Nechushtai, Rachel
Priority Date: 17 Aug 2007
Priority Number: US8350007B2
Application Date: 21 Jul 2011
Publication Date: 8 Jan 2013
IPC Current: C07K000100
US Class: 530350
Assignee Applicant: The Regents of the University of California
Title: Crystal structure of human mitoNEET protein
Usefulness: Crystal structure of human mitoNEET protein
Summary: As human mitochondrial membrane protein crystal for identifying a compound for the treatment of a mitoNEET-associated disorder selected from type II diabetes, insulin resistance, multiple sclerosis, Alzheimer's disease or amyotrophic lateral sclerosis (claimed), Syndrome X, hyperinsulemia, obesity, dyslipidemia, heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa, cardiovascular diseases and conditions including hypertension, atherosclerosis, arteriosclerosis and hypertriglyceridemia.
Novelty: New crystal comprising a human mitochondrial membrane protein having specific amino acid sequence, useful for identifying a compound for treating e.g. type II diabetes, insulin resistance, multiple sclerosis, Alzheimer's disease, obesity
Chemical/Material
Chemical/Material Application
8350007
Related Materials Tech ID/UC Case 19440/2008-040-0 Related Cases 2008-040-0
USA
